NYSE: STE |
| Healthcare / Medical Devices & Instruments / USA |
230.71 | +2.29 | +1.00% | Vol 271.01K | 1Y Perf 17.64% |
May 26th, 2022 16:00 DELAYED |
BID | 209.01 | ASK | 368.89 | ||
Open | 230.07 | Previous Close | 230.71 | ||
Pre-Market | - | After-Market | 231.18 | ||
- - | 0.47 0.20% |
Target Price | 261.80 | Analyst Rating | Strong Buy 1.25 | |
Potential % | 13.48 | Finscreener Ranking | ★★ 45.09 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★ 45.73 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★+ 50.19 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | ★★ 38.12 | |
Price Range Ratio 52W % | 62.82 | Earnings Rating | Neutral | |
Market Cap | 23.10B | Earnings Date | 11th May 2022 | |
Alpha | 0.01 | Standard Deviation | 0.06 | |
Beta | 0.67 |
Today's Price Range 228.89231.17 | 52W Range 188.10255.93 | 5 Year PE Ratio Range 26.6074.50 |
Summary:
Buy
Technical Indicators: | Buy |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Week | 2.11% | ||
1 Month | -0.26% | ||
3 Months | -2.79% | ||
6 Months | 1.50% | ||
1 Year | 17.64% | ||
3 Years | 70.76% | ||
5 Years | 199.23% | ||
10 Years | 716.77% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 7.45 | |||
ROE last 12 Months | 4.78 | |||
ROA (5Y Avg) | 3.01 | |||
ROA last 12 Months | 2.76 | |||
ROC (5Y Avg) | 5.92 | |||
ROC last 12 Months | 4.18 | |||
Return on invested Capital Q | 0.54 | |||
Return on invested Capital Y | 3.22 | |||
Assets Turnover | 0.50 | |||
Receivables Turnover | 6.50 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
94.50 | ||||
3.46 | ||||
4.97 | ||||
32.40 | ||||
-154.30 | ||||
6.96 | ||||
3.46 | ||||
65.36 | ||||
25.22B | ||||
Forward PE | 22.98 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.20 | ||||
2.00 | ||||
0.31 | ||||
0.45 | ||||
5.90 | ||||
Leverage Ratio | 1.80 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
44.00 | ||||
10.80 | ||||
19.70 | ||||
13.10 | ||||
5.35 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
4.59B | ||||
45.79 | ||||
16.46 | ||||
10.23 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.76 | ||||
1.72 | ||||
8.31 | ||||
9.14 | ||||
Payout ratio | 33.00 |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q04 2022 | 2.00 | 2.04 | 2.00 |
Q03 2022 | 1.95 | 2.12 | 8.72 |
Q02 2022 | 1.83 | 1.99 | 8.74 |
Q01 2022 | 1.50 | 1.76 | 17.33 |
Q04 2021 | 1.80 | 1.63 | -9.44 |
Q03 2021 | 1.56 | 1.73 | 10.90 |
Q02 2021 | 1.24 | 1.48 | 19.35 |
Q01 2021 | 0.97 | 1.31 | 35.05 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | 1.86 | -78.82 | Negative |
9/2022 QR | 2.12 | -78.43 | Negative |
3/2023 FY | 8.71 | - | - |
3/2024 FY | 9.83 | - | - |
Next Report Date | - |
Estimated EPS Next Report | 2.00 |
Estimates Count | 1 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 271.01K |
Shares Outstanding | 100.13K |
Shares Float | 90.79M |
Trades Count | 11.13K |
Dollar Volume | 62.40M |
Avg. Volume | 437.14K |
Avg. Weekly Volume | 418.28K |
Avg. Monthly Volume | 437.61K |
Avg. Quarterly Volume | 455.53K |
STERIS plc (Ireland) (NYSE: STE) stock closed at 230.71 per share at the end of the most recent trading day (a 1% change compared to the prior day closing price) with a volume of 271.01K shares and market capitalization of 23.10B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 13000 people. STERIS plc (Ireland) CEO is Daniel A. Carestio.
The one-year performance of STERIS plc (Ireland) stock is 17.64%, while year-to-date (YTD) performance is -5.22%. STE stock has a five-year performance of 199.23%. Its 52-week range is between 188.1 and 255.9325, which gives STE stock a 52-week price range ratio of 62.82%
STERIS plc (Ireland) currently has a PE ratio of 94.50, a price-to-book (PB) ratio of 3.46, a price-to-sale (PS) ratio of 4.97, a price to cashflow ratio of 32.40, a PEG ratio of 2.32, a ROA of 2.76%, a ROC of 4.18% and a ROE of 4.78%. The company’s profit margin is 5.35%, its EBITDA margin is 19.70%, and its revenue ttm is $4.59 Billion , which makes it $45.79 revenue per share.
Of the last four earnings reports from STERIS plc (Ireland), there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.00 for the next earnings report. STERIS plc (Ireland)’s next earnings report date is -.
The consensus rating of Wall Street analysts for STERIS plc (Ireland) is Strong Buy (1.25), with a target price of $261.8, which is +13.48% compared to the current price. The earnings rating for STERIS plc (Ireland) stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
STERIS plc (Ireland) has a dividend yield of 0.76% with a dividend per share of $1.72 and a payout ratio of 33.00%.
STERIS plc (Ireland) has a Buy technical analysis rating based on Technical Indicators (ADX : 9.15, ATR14 : 6.04, CCI20 : 113.15, Chaikin Money Flow : 0.11, MACD : -1.63, Money Flow Index : 70.54, ROC : 7.12, RSI : 54.29, STOCH (14,3) : 97.92, STOCH RSI : 1.00, UO : 64.76, Williams %R : -2.08), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of STERIS plc (Ireland) in the last 12-months were: Andrew Xilas (Option Excercise at a value of $0), Cary L Majors (Sold 12 950 shares of value $2 857 217 ), Cynthia L. Feldmann (Option Excercise at a value of $135 017), Cynthia L. Feldmann (Sold 1 891 shares of value $442 683 ), J. Adam Zangerle (Option Excercise at a value of $543 840), J. Adam Zangerle (Sold 8 000 shares of value $2 043 876 ), Jacqueline B. Kosecoff (Option Excercise at a value of $104 134), Jacqueline B. Kosecoff (Sold 3 218 shares of value $756 874 ), Karen L. Burton (Option Excercise at a value of $489 552), Karen L. Burton (Sold 6 600 shares of value $1 588 786 ), Michael J. Tokich (Option Excercise at a value of $3 451 200), Michael J. Tokich (Sold 58 000 shares of value $13 900 000 ), Renato Tamaro (Option Excercise at a value of $147 729), Renato Tamaro (Sold 1 449 shares of value $309 550 ), Richard C. Breeden (Option Excercise at a value of $98 655)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Steris PLC is a medical device company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Its operating segment includes Healthcare, Applied Sterilization Technologies, and Life Sciences. The company generates maximum revenue from Healthcare segment.
CEO: Daniel A. Carestio
Telephone: +1 440 354-2600
Address: 5960 Heisley Road, Mentor 44060, OH, US
Number of employees: 13 000
Thu, 12 May 2022 10:15 GMT Analysts Offer Insights on Healthcare Companies: Biolinerx (BLRX), Steris (STE) and TRACON Pharmaceuticals (TCON)
- TipRanks. All rights reserved.Tue, 12 Apr 2022 09:25 GMT Needham Believes Steris (STE) Still Has Room to Grow
- TipRanks. All rights reserved.Wed, 16 Feb 2022 09:52 GMT Steris Updates 1 Key Risk Factor
- TipRanks. All rights reserved.Wed, 09 Feb 2022 05:35 GMT Analysts Offer Insights on Healthcare Companies: Steris (STE) and Enanta Pharmaceuticals (ENTA)
- TipRanks. All rights reserved.Wed, 26 Jan 2022 09:45 GMT Inside Evoqua Water Technologies Newly Added Risk Factors
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.